ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 1914

Racial and Ethnic Differences in the Prevalence of Disease Features in Systemic Sclerosis

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 1924

Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 1909

Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 2388

Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1973

Radioisotopic Synoviorthesis: Factors Associated with Good Response Evaluated by Ultrasound

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 2466

Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2159

Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education

Patient Outcomes, Preferences, & Attitudes Poster III

10:30AM-12:30PM: Abstract Number: 2284

Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2484

Real-World Use of Avacopan for ANCA-Associated Vasculitis Beyond 52 Weeks

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 1899

Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2370

Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1865

Reduction in CD4+T Cell Expression of CD28 and CD2 by Antibody-induced Internalization of CD6: A Potential Step Towards Immune Tolerance

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1764

Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2438

Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1936

Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries

Health Services Research – ACR/ARP Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].